Cartesian Therapeutics (RNAC) Tops Q2 EPS by 50c
Get Alerts RNAC Hot Sheet
Join SI Premium – FREE
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.50. Revenue for the quarter came in at $300 thousand.
For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
- Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share